Loading...
•
Sep 30, 2024
United Therapeutics Q3 2024 Earnings Report
Reported record revenue for a sixth straight quarter, driven by increasing demand for innovative products.
Key Takeaways
United Therapeutics reported a strong third quarter in 2024, with total revenues growing by 23% year-over-year to $748.9 million. The company achieved a $3 billion annual revenue run rate and saw significant growth in Tyvaso revenues. They are anticipating clinical data reads and regulatory events to further propel growth.
Total revenues increased by 23% year-over-year to $748.9 million.
Net income rose by 16% to $309.1 million.
Tyvaso revenues grew by 33% to $433.8 million.
The company is progressing with clinical studies and regulatory filings for future growth.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics anticipates a multi-year cascade of clinical data reads and regulatory events that should continue to propel growth through the balance of the decade and beyond.
Positive Outlook
- Data expected for the TETON studies in idiopathic pulmonary fibrosis.
- Data expected for ADVANCE OUTCOMES in pulmonary arterial hypertension.
- Data from the miroliverELAP phase 1 study now underway for acute liver failure.
- Potential launch of the UKidney human clinical program.
- Filing of an investigational new drug application for UKidney is expected shortly.
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties.
- Actual results could differ materially from anticipated results.
- The amount ultimately payable in litigation with Sandoz Inc., if any, could be higher or lower than the current accrual.
- Share-based compensation expense increased due to a greater number of awards remaining outstanding.
- The company's future performance is subject to the risks described in its periodic reports filed with the Securities and Exchange Commission.
Revenue & Expenses
Visualization of income flow from segment revenue to net income